THERAPY DOSSIER · th-bdccee77f8e0

Kaempferol

Nutraceutical · Dietary flavonoid; antioxidant (no ChEMBL mechanism record).

Evidence & regulatory context

Mechanism: Dietary flavonoid; antioxidant (no ChEMBL mechanism record).
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL150 ↗
ChEMBL max phase: 1 / 4 (development scale, not regulatory approval)
Synonyms: Kaempherol; Robigenin; Trifolitin
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06060691 ↗PHASE1completed

Kaempferol Emulgel on Female Arousal Disorder / Sexual Dysfunction

Female Sexual Dysfunction

Enrolment: 30 · Results not recorded

NCT07458334 ↗NArecruiting

Skincare Benefits of Kaempferol-Containing Masks

Skin Biophysical Properties

Enrolment: 60 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30430900 ↗2019Reported benefit

Beneficial Effects of Kaempferol after Developmental Traumatic Brain Injury Is through Protection of Mitochondrial Function, Oxidative Metabolism, and Neural Viability.

RatTBIUnspecifiedSprague-DawleyMaleIntraperitoneal1 mg/kgFirst dose 1 h after injury

Model: Mild to moderate traumatic brain injury during early development; injury device, force and duration not stated

Kaempferol improved tricarboxylic acid cycle flux, decreased acyl carnitines, raised N-acetyl aspartate and improved sensorimotor behaviour compared with vehicle and untreated injured animals.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…